Acute exposure to an electric field induces changes in human plasma lysophosphatidylcholine (lysoPC)-22:4 levels: Molecular insight into the docking of lysoPC-22:4 interaction with TRPV2

Nakagawa-Yagi Y1*, Hara H1, Nakanishi H2, Tasaka T3 and Hara A1

1 Hakuju Institute for Health Science Co., Ltd., 37-5 Tomigaya 1-chome, Shibuya-ku, Tokyo, Japan
2 Akita Lipid Technologies LLC., 1-2 Nukazuka, Yanagida, Akita, Akita, Japan
3 Affinity Science Corporation, 1-1-1 Nishigotanda, Shinagawa-ku, Tokyo, Japan

Abstract

Medical treatment using high-voltage electric potential (HELP) devices to generate an electric field (EF) is an alternative therapy commonly used in Japan. However, the underlying mechanisms of the potential health benefits are not fully understood. To address this issue, we investigated the levels of lyso-form phospholipids using selected reaction monitoring (SRM) analysis in plasma samples obtained from healthy human subjects before and after a single HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min). Lysophosphatidylcholine (lysoPC)-22:4 was significantly upregulated after HELP exposure. However, there was no effect on the levels of lysophosphatidic acid (lysoPA), or other lysoPC species. LysoPC is known to accelerate intestinal movement as a putative endogenous activator of transient receptor potential vanilloid 2 (TRPV2). We further examined the in silico docking simulation of lysoPC-22:4 with TRPV2. Docking results showed that lysoPC-22:4 has good binding energy (-8.2 kcal/mol). Our findings provide new insight into the molecular mechanisms of constipation alleviation by EF therapy.

Abbreviations

EF: electric field; FA: fatty acid; GPR119: G protein-coupled receptor 119; HELP: high-voltage electric potential; lysoPA: lysophosphatidic acid; lysoPC: lysophosphatidylcholine; lysoPC-22:4 : (2-[(2R)-3-[(7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoyloxy]-2-hydropropyl phosphonato[oxy]ethyl]trimethylazanium; PA: phosphatidic acid; PC: phosphatidylcholine; RTx: resiniferatoxin; SRM: selected reaction monitoring; TRPM8: transient receptor potential melastatin 8; TRPV1: transient receptor potential vanilloid 1; and TRPV2: transient receptor potential vanilloid 2

Introduction

A therapeutic device to expose the human body to high-voltage electric potential (HELP) has been approved by the Ministry of Health, Labour and Welfare in Japan [1-15]. High-voltage electric field (EF) therapy is reported to be an effective treatment for stiff shoulders, headache, insomnia, and chronic constipation [1-15]. In the case of constipation, considerable evidence of efficacy has been obtained from several clinical studies of functional constipation and chronic constipation [16-17]. Taken together, the results of these studies suggest that HELP exposure may present an alternative therapy for several conditions, although the mechanisms of action remain elusive. Our previous attempts to find a HELP exposure-induced biomarker using plasma metabolomics have led to the detection of lipid-derived signaling molecules such as oleoylethanolamide (OEA), cis-8,11,14-eicosatrienoic acid, 9-hydroxyoctadecadienoic acid (9-HODE), 13-HODE, 13-hydroperoxyoctadecadienoic acid (13-HpODE), and 3-hydroxybutyrate [18-21]. Endogenous lipid-derived signaling molecules have been suggested as candidate molecules that represent the interface between symptoms and electroceutical target proteins [18-21]. Currently, more recent methods for the quantification of lipid-derived signaling molecules have taken advantage of SRM analysis [22-26]. Therefore, we hypothesized that increased plasma fatty acid levels after EF exposure may be linked to changes in lyso-form phospholipids in plasma. A recent study by Mihara et al. reported that gastrointestinal transit in vivo is accelerated by the lyso-form phospholipid lysoPC [27]. The observations of Mihara et al. led us to study changes in lysoPC, using SRM analysis on plasma samples obtained from healthy subjects before and after exposure to a single HELP stimulation [27]. Here we report that lysoPC-22:4 can be upregulated by HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min). Because lysoPC treatment of isolated myenteric neurons induces transient receptor potential vanilloid 2 (TRPV2)-mediated responses [27], we carried out a binding study using AutoDock Vina docking software to explore the interactions of lysoPC-22:4 with the active site of TRPV2.

Correspondence to: Yuzo Nakagawa-Yagi, Ph.D, Hakuju Institute for Health Science Co., Ltd., 37-5 Tomigaya 1-chome, Shibuya-ku, Tokyo, Japan, E-mail: yagi@hakuju.co.jp

Key words: lysophosphatidylcholine, lysoPC-22:4, TRPV2, lipidomics, electric field therapy

Received: March 07, 2017; Accepted: March 15, 2017; Published: March 18, 2017
Materials and methods

EF exposure

The system used for EF exposure has been previously described [18-21]. The EF system was equipped with a transformer, a seat, and two insulator-covered electrodes. One electrode was placed on a floor plate on which the subject's feet were located, and the other was placed above the subject's head. EF generated by the HELP apparatus (Healthtron PRO-18T; Hakuju Institute for Health Science Co., Ltd., Tokyo, Japan) was uniformly created by transforming a 50 Hz alternating current at 18 kV (9 kV/electrode + 9 kV/electrode). The safety of this system for human use was established by the Japanese government in 1963.

Subjects

Fifty healthy adults [21 males and 29 females; mean age, 46.5 ± 0.9 years; mean body mass index (BMI), 21.9 ± 0.4 kg/m²] participated in experiment 1 (exposure condition: 9 kV/electrode + 9 kV/electrode, 30 min). Twenty-five healthy adults (9 males and 16 females; mean age, 46.1 ± 1.1 years; BMI, 22.2 ± 0.5 kg/m²) participated in experiment 2 (exposure condition: 9 kV/electrode + 9 kV/electrode, 30 min). All experiments were performed in the morning and all participants signed an informed consent form after receiving verbal and written information about the study. All experiments were conducted in accordance with the Declaration of Helsinki and the study protocol was approved by the human ethics committee of Hakuju Institute for Health Science Co., Ltd. (Tokyo, Japan).

Plasma preparation

Blood samples were collected in vacutainer tubes coated with ethylenediaminetetraacetic acid (VP-NA070K; Terumo Corporation, Tokyo, Japan) and immediately centrifuged at 800 x g for 5 min to separate plasma from other cellular materials. Plasma was then transferred to a fresh Eppendorf tube and stored at -80°C until processing.

Phospholipid preparation

Comprehensive analysis of phospholipids was conducted in essentially the same manner as described previously [28-29]. Briefly, total phospholipids were extracted from the plasma with the Bligh-Dyer method [30]. Aliquots of the lower/organic phase were transferred to a fresh Eppendorf tube and stored at -80°C until processing.

Mass spectrometric analyzes

LC-electrospray ionization-MS/MS analysis was performed with an UltiMate 3000 LC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with HTCL PAL autosampler (CTC Analytics AG, Lake Elmo, MN, USA). A 10 µL aliquot of the lipid samples was injected and the lipids were separated on a Waters X-Bridge C18 (3.5 µm, 150 mm x 1.0 mm i.d., Waters Corporation, Milford, MA, USA) at room temperature (25°C) using a gradient solvent system as follows: mobile phase A [isopropanol/methanol/water (5:1:4, v/v/v)] supplemented with 5 mM ammonium formate and 0.05% ammonium hydroxide; mobile phase B (isopropanol supplemented with 5 mM ammonium formate and 0.05% ammonium hydroxide) ratios of 70%/30% (0 min), 50%/50% (2 min), 20%/80% (13 min), 5%/95% (15 - 30 min), 95%/5% (31 - 35 min), and 70%/30% (35-45 min). Flow rate was 20 µL/min. Phospholipid species were measured by selected reaction monitoring (SRM) in positive ion mode with a TSQ Vantage AM mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The characteristic fragments of individual phospholipids were detected by the product ion scan (MS/MS mode). Chromatographic peak areas were used for comparative quantitation of each molecular species (e.g., 38:6, 40:6) in a given class of the phospholipids (e.g., PA, PC). The specific detection of individual lipids was performed using multiple reaction monitoring. Multiple reaction monitoring (MRM) m/z transitions were lysoPC-22:4 = 572.4 /184.1.

Molecular modeling and docking study

We assessed lysoPC in the plasma obtained from 50 healthy participants using SRM analysis (Figure 1 and Figure 2). HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min) resulted in significantly higher plasma levels of lysoPC-22:4 than pre-exposure levels (1.47-fold; p=0.027). Under these conditions, HELP exposure did not affect the levels of lysoPC-14:0, lysoPC-16:0, lysoPC-16:1, lysoPC-18:0, lysoPC-18:1, lysoPC-18:2, lysoPC-20:0, lysoPC-20:1, lysoPC-20:2, lysoPC-20:3, lysoPC-20:4, lysoPC-20:5, lysoPC-22:5, or lysoPC-22:6 (Figure 2).

We assessed PC in the plasma obtained from 50 healthy participants using SRM analysis. HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min) did not affect the levels of PC-32:0, PC-34:0, PC-34:1, PC-34:2, PC-36:0, PC-36:1, PC-36:2, PC-36:3, PC-36:4, PC-38:4, PC-40:4, PC-40:5, or PC-40:6 (Figure 3).

Effect of HELP exposure on lysoPA and PA in plasma from healthy humans

We assessed lysoPA in the plasma obtained from 25 healthy participants using SRM analysis (Figure 4). HELP exposure did not affect the levels of lysoPA-16:0, lysoPA-18:0, lysoPA-18:1, lysoPA-18:2, lysoPA-20:4, or lysoPA-22:6 (Figure 4).

We assessed PA in the plasma obtained from 25 healthy participants using SRM analysis. HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min) did not affect the levels of PA-32:0, PA-32:1, PA-34:0, PA-34:1, PA-34:2, PA-36:0, PA-36:1, PA-36:2, PA-36:3, PA-36:4, PA-38:3, PA-38:4, PA-38:5, PA-38:6, PA-40:4, PA-40:5, or PA-40:6 (Figure 5).
Nakagawa-Yagi Y (2017) Acute exposure to an electric field induces changes in human plasma lysophosphatidylcholine (lysoPC)-22:4 levels: Molecular insight into the docking of lysoPC-22:4 interaction with TRPV2

Docking of lysoPC-22:4 on TRPV2

LysoPC is known to induce gastrointestinal tract transit as an activator of TRPV2 [27]. Therefore, we hypothesized that increased plasma lysoPC-22:4 levels after HELP exposure may be linked to alleviation of constipation in humans. We examined the in silico docking of lysoPC-22:4 in the active site of TRPV2 using AutoDock Vina software. We set the number of output poses to 20, with a total of 100 candidate conformations. Cluster analysis was performed using

Figure 1. Lipidomic analysis of the plasma of healthy humans before and after HELP exposure for 30 min. Typical lysoPC-22:4 peak in the plasma of healthy humans. LysoPC-22:4 was detected by SRM analysis.

Figure 2. Effect of HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min) on lysoPC in the plasma of healthy humans. Relative ratio (after/before) of lysoPC in plasma before and after EF exposure. Results are presented as mean ± SEM (n = 50). * p < 0.05 compared with before.

Figure 3: Effect of HELP exposure (9 kV/electrode + 9 kV/electrode, 30 min) on PC in the plasma of healthy humans. Relative ratio (after/before) of PC in plasma before and after EF exposure. Results are presented as mean ± SEM (n = 50).
KNIME [33], and classified results into 32 conformation groups. Table 1 shows the obtained docking score and cluster ID. As shown in Table 1, the conformation group of the cluster ID-31 was the largest. Next, eight conformations of cluster ID-31 with binding energies lower than -7.85 kcal/mol were compared. As shown in Table 1, the conformation group of the cluster ID-31 was the best configuration (seed: 101, mode 1) with lowest binding energy -8.2 kcal/mol (Table 1, Figure 6b). LysoPC-22:4 formed hydrogen bonds with Ser526, Gln530, and Asn639 (Figure 6c). The results indicated that lysoPC-22:4 would bind to the TRPV2 channel.

Discussion
In this study, we showed that lysoPC-22:4 in healthy human subjects is sensitive to acute EF exposure. Notably, the absence of lysoPA response indicates that the response to lysoPC-22:4 is not by an adverse nonspecific action on membrane lipids. The molecular mechanisms of

Table 1. Docking score and cluster ID.

<table>
<thead>
<tr>
<th>Pocket</th>
<th>Seed</th>
<th>101</th>
<th>102</th>
<th>103</th>
<th>104</th>
<th>105</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Affinity kcal/mol</td>
<td>Cluster ID</td>
<td>Affinity kcal/mol</td>
<td>Cluster ID</td>
<td>Affinity kcal/mol</td>
<td>Cluster ID</td>
</tr>
<tr>
<td>Mode 1</td>
<td>-8.2</td>
<td>31</td>
<td>-8.0</td>
<td>22</td>
<td>-8.1</td>
<td>31</td>
</tr>
<tr>
<td>Mode 2</td>
<td>-8.1</td>
<td>32</td>
<td>-7.9</td>
<td>31</td>
<td>-8.0</td>
<td>28</td>
</tr>
<tr>
<td>Mode 3</td>
<td>-8.1</td>
<td>30</td>
<td>-7.8</td>
<td>31</td>
<td>-7.9</td>
<td>31</td>
</tr>
<tr>
<td>Mode 4</td>
<td>-8.0</td>
<td>28</td>
<td>-7.8</td>
<td>5</td>
<td>-7.8</td>
<td>7</td>
</tr>
<tr>
<td>Mode 5</td>
<td>-7.9</td>
<td>31</td>
<td>-7.7</td>
<td>31</td>
<td>-7.8</td>
<td>8</td>
</tr>
<tr>
<td>Mode 6</td>
<td>-7.9</td>
<td>31</td>
<td>-7.7</td>
<td>32</td>
<td>-7.8</td>
<td>25</td>
</tr>
<tr>
<td>Mode 7</td>
<td>-7.9</td>
<td>32</td>
<td>-7.7</td>
<td>31</td>
<td>-7.8</td>
<td>31</td>
</tr>
<tr>
<td>Mode 8</td>
<td>-7.8</td>
<td>1</td>
<td>-7.7</td>
<td>31</td>
<td>-7.7</td>
<td>31</td>
</tr>
<tr>
<td>Mode 9</td>
<td>-7.8</td>
<td>2</td>
<td>-7.7</td>
<td>25</td>
<td>-7.7</td>
<td>9</td>
</tr>
<tr>
<td>Mode 10</td>
<td>-7.8</td>
<td>22</td>
<td>-7.6</td>
<td>31</td>
<td>-7.6</td>
<td>26</td>
</tr>
<tr>
<td>Mode 11</td>
<td>-7.8</td>
<td>24</td>
<td>-7.6</td>
<td>26</td>
<td>-7.6</td>
<td>29</td>
</tr>
<tr>
<td>Mode 12</td>
<td>-7.7</td>
<td>32</td>
<td>-7.6</td>
<td>23</td>
<td>-7.6</td>
<td>10</td>
</tr>
<tr>
<td>Mode 13</td>
<td>-7.7</td>
<td>20</td>
<td>-7.6</td>
<td>28</td>
<td>-7.6</td>
<td>32</td>
</tr>
<tr>
<td>Mode 14</td>
<td>-7.7</td>
<td>3</td>
<td>-7.6</td>
<td>32</td>
<td>-7.5</td>
<td>25</td>
</tr>
<tr>
<td>Mode 15</td>
<td>-7.7</td>
<td>20</td>
<td>-7.6</td>
<td>23</td>
<td>-7.5</td>
<td>27</td>
</tr>
<tr>
<td>Mode 16</td>
<td>-7.7</td>
<td>25</td>
<td>-7.5</td>
<td>32</td>
<td>-7.5</td>
<td>11</td>
</tr>
<tr>
<td>Mode 17</td>
<td>-7.7</td>
<td>4</td>
<td>-7.5</td>
<td>19</td>
<td>-7.5</td>
<td>32</td>
</tr>
<tr>
<td>Mode 18</td>
<td>-7.7</td>
<td>19</td>
<td>-7.5</td>
<td>30</td>
<td>-7.5</td>
<td>26</td>
</tr>
<tr>
<td>Mode 19</td>
<td>-7.7</td>
<td>32</td>
<td>-7.5</td>
<td>22</td>
<td>-7.4</td>
<td>28</td>
</tr>
<tr>
<td>Mode 20</td>
<td>-7.5</td>
<td>31</td>
<td>-7.4</td>
<td>6</td>
<td>-7.4</td>
<td>27</td>
</tr>
</tbody>
</table>
changes in lysoPC-22:4 levels following EF exposure are complex and can be interpreted in several ways. Interestingly, Thuren et al. reported that phospholipase A \(_2\) (PLA\(_2\))-catalyzed hydrolysis is elevated by EF [34]. PLA\(_2\) enzymes hydrolyze the ester of glycerophospholipids to release lysophospholipids and a free unsaturated fatty acid [35]. In plasma metabolomics, we have previously documented EF exposure (9 kV/electrode + 9 kV/electrode)-induced increases of approximately 1.52-fold, 1.47-fold, 1.41-fold, 1.46-fold, and 1.51-fold for oleic acid, linoleic acid, arachidonic acid (FA-20:4), FA-22:4, FA-22:5, and \(\text{cis}-4,7,10,13,16,19\)-docosahexaenoic acid (FA-22:6), respectively [18]. The results of the present study showed that EF exposure induced a 1.47-fold increase in human plasma lysoPC-22:4 levels. Thus, it is reasonable to speculate that EF exposure upregulates lysoPC-22:4 through the activation of PLA\(_2\). Further studies are needed to identify the lysoPC-22:4 signaling pathways induced by EF exposure.

Another goal of the present study was to gain insight into the molecular mechanisms of constipation alleviation by EF therapy. Interestingly, Mihara et al. reported that intragastric administration of TRPV2 agonists such as probenecid and lysoPC induced an enhancement of gastrointestinal transit in vivo through TRPV2 activation in mice [22]. Unfortunately, there is no commercially available lysoPC-22:4 as a pure chemical reagent for pharmacological experiments. Thus, it will take some time for us to investigate the effects of lysoPC-22:4 on gastrointestinal tract transit in vivo. An increasing number of reports on virtual simulation have appeared in the literature [18-19, 36-37]. In silico molecular docking studies have been used to support their pharmacological results. To date, research regarding the effect of endogenous ligand on TRPV2 channels is scarce [38-39]. Most published studies were carried out using a TRPV1 model [40-43]. Prescott et al. reported activation of the TRPV1 channel by phosphatidylinositol 4,5-biphosphate (PIP\(_2\)) [44], while Nieto-Posadas et al. reported lysoPA-stimulated TRPV1 channel activation through a C-terminal binding site [45]. TRPV1 shares about 50 % sequence identity with TRPV2 [46]. Huynh et al. recently reported the structure of the full-length rat TRPV2 channel by cryo-electron microscopy [38], while Zubcevic et al. reported the atomic model of rabbit TRPV2 [39]. In crystallographic analyses of human TRPV2, there is limited information on the structure of the ankyrin repeat domain of TRPV2. In the present study, the docking analysis showed that lysoPC-22:4 has good binding affinity (~8.2 kcal/mol). Moreover, it interacted with Ser526, Gln530, and Asn639. Interestingly, a previous study of rat TRPV2 channels with resifenriatexin (RTx) binding pockets reported hydrogen bonding to Gln530 [47]. Further studies are needed to identify a putative lysoPC-22:4 binding pocket in human TRPV2.

In conclusion, acute EF exposure exerted marked effects on plasma lysoPC-22:4 levels in healthy subjects, and in silico molecular docking of lysoPC-22:4 was observed for the TRPV2 channel. Our findings provide insight into the molecular mechanisms behind the health benefits induced by the HELP device, which may also be important for gastrointestinal motility.

Competing interests

Yuzo Nakagawa-Yagi, Hiroyuki Hara, Akikuni Hara are employed by Hakuju Institute for Health Science Co., Ltd., HN is employed by Akita Lipid Technologies LLC., and TT is employed by Affinity Science Corporation. All other authors have no competing interests.

Authors’ contributions

Yuzo Nakagawa-Yagi designed and supervised the research, and wrote the manuscript. Hiroki Nakanishi performed SRM. Tomohiko Tasaka performed the molecular modeling. Yuzo Nakagawa-Yagi, Hiroyuki Hara, and Akikuni Hara performed the biophysical experiments. All authors have read and approved the final version of the manuscript.

Acknowledgment

We thank Dr. Makoto Kikuchi (Professor Emeritus, National Defense Medical College, Japan) for encouragement.

References


Figure 6: View of the conformation of lysoPC-22:4 docked in the TRPV2 channel. (a) Eight conformations of cluster ID-31 with binding energies lower than −7.85 kcal/mol. (b) Best conformation of lysoPC-22:4 (seed: 101, mode 1) with lowest binding energy (~8.2 kcal/mol). (c) Binding mode of lysoPC-22:4 in TRPV2 channel.
potential vanilloid 2 (TRPV2) ion channel. FEBS J 280: 5471-5487.

Copyright: ©2017 Nakagawa-Yagi Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.